Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Theunis, Clara ^a   Crespo Biel, Natalia ^a   Gafner, Valérie ^b   Pihlgren, Maria ^b   López Deber, María Pilar ^b   Reis, Pedro ^b   Hickman, David T ^b   Adolfsson, Oskar ^b   Chuard, Nathalie ^b   Ndao, Dorin Mlaki ^b   Borghgraef, Peter ^a   Devijver, Herman ^a   Van Leuven, Fred ^a   Pfeifer, Andrea ^b   Muhs, Andreas ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b AC IMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACI 35 VACCINE; EPITOPE; TAU PROTEIN; UNCLASSIFIED DRUG; VACCINE; ALZHEIMER DISEASE VACCINE; LIPOSOME; NEUTRALIZING ANTIBODY; PEPTIDE; PHOSPHOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LIPOSOMAL DELIVERY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TAUOPATHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PSYCHOMOTOR PERFORMANCE; SYNTHESIS; TAUOPATHIES; TRANSGENIC MOUSE; TREATMENT OUTCOME; VACCINATION;

MUS;

ALZHEIMER VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; LIPOSOMES; MICE; MICE, TRANSGENIC; PEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PSYCHOMOTOR PERFORMANCE; TAU PROTEINS; TAUOPATHIES; TREATMENT OUTCOME; VACCINATION;

EID: 84922479255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072301     Document Type: Article

References (72)

1. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 5: 1858-1862.
2. Cleveland DW, Hwo SY, Kirschner MW (1977) Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol 2: 227-247.
3. Chen J, Kanai Y, Cowan NJ, Hirokawa N (1992) Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 6405: 674-677.
4. Rosenberg KJ, Ross JL, Feinstein HE, Feinstein SC, Israelachvili J (2008) Complementary dimerization of microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis. Proc Natl Acad Sci U S A 21: 7445-7450.
5. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, et al. (1993) Microtubuleassociated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 32: 24374-24384.
6. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer's 1907 paper, ''Uber eine eigenartige Erkankung der Hirnrinde''. Clin Anat 6: 429-431.
7. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 4: 239-259.
8. Mitchell TW, Nissanov J, Han LY, Mufson EJ, Schneider JA, et al. (2000) Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem 12: 1627-1638.
9. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 1: 5-36.
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 3 Pt 1: 631-639.
11. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, et al. (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 6: 1158-1165.
12. Crespo-Biel N, Theunis C, van Leuven F. (2012) Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis 251426.
13. Sumi SM, Bird TD, Nochlin D, Raskind MA (1992) Familial presenile dementia with psychosis associated with cortical neurofibrillary tangles and degeneration of the amygdala. Neurology 1: 120-127.
14. Spillantini MG, Goedert M (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci 10: 428-433.
15. Crowther RA, Goedert M (2000) Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol 2-3: 271-279.
16. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J (2006) Therapeutic approaches to Alzheimer's disease. Brain Pt 11: 2840-2855.
17. Rafii MS, Aisen PS (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med 7.
18. Herrmann N, Chau SA, Kircanski I, Lanctot KL (2011) Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 15: 2031-2065.
19. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloidbeta peptide: a case report. Nat Med 4: 448-452.
20. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 9: 1553-1562.
21. Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ (2002) A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A 4: 2332-2337.
22. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, et al. (2007) Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 23: 9810-9815.
23. Hickman DT, Lopez-Deber MP, Ndao DM, Silva AB, Nand D, et al. (2011) Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 16: 13966-13976.
24. Pihlgren M, Silva AB, Madani R, Giriens V, Waeckerle-Men Y, et al. (2013) TLR4 and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T-cell independent isotype switch in mice. Blood 1: 85-94.
25. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1: 58-62.
26. Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 15: 5827-5831.
27. Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, et al. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 6: 669-673.
28. Buee-Scherrer V, Condamines O, Mourton-Gilles C, Jakes R, Goedert M, et al. (1996) AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res 1-2: 79-88.
29. Torreilles F, Roquet F, Granier C, Pau B, Mourton-Gilles C (2000) Binding specificity of monoclonal antibody AD2: influence of the phosphorylation state of tau. Brain Res Mol Brain Res 1-2: 181-185.
30. Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, et al. (2005) Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 5: 3963-3973.
31. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, et al. (2008) Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 3: 786-798.
32. Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, et al. (2006) Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. Journal of Neuroscience 13: 3514-3523.
33. Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, et al. (2010) Alzheimer's disease: old problem, new views from transgenic and viral models. Biochim Biophys Acta 10: 808-818.
34. Dutschmann M, Menuet C, Stettner GM, Gestreau C, Borghgraef P, et al. (2010) Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei. Journal of Neuroscience 5: 1810-1821.
35. Menuet C, Cazals Y, Gestreau C, Borghgraef P, Gielis L, et al. (2011) Agerelated impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders. PLoS One 10: e25770.
36. Menuet C, Borghgraef P, Matarazzo V, Gielis L, Lajard AM, et al. (2011) Raphe tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease. Respir Physiol Neurobiol 2: 290-303.
37. Kremer A, Maurin H, Demedts D, Devijver H, Borghgraef P, et al. (2011) Early Improved and Late Defective Cognition Is Reflected by Dendritic Spines in Tau.P301L Mice. Journal of Neuroscience 49: 18036-18047.
38. Maurin H, Seymour CM, Lechat B, Borghgraef P, Devijver H, et al. (2013) Tauopathy differentially affects Cell Adhesion Molecules in mouse brain: early down-regulation of Nectin-3 in Stratum Lacunosum Moleculare. PLoS One May 21, 2013.
39. Vandebroek T, Vanhelmont T, Terwel D, Borghgraef P, Lemaire K, et al. (2005) Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 34: 11466-11475.
40. Vandebroek T, Terwel D, Vanhelmont T, Gysemans M, Van Haesendonck C, et al. (2006) Microtubule binding and clustering of human Tau-4R and Tau- P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem 35: 25388-25397.
41. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, et al. (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 10: 1459-1467.
42. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, et al. (2003) Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain Pt 2: 285-291.
43. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 1: 46-54.
44. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, et al. (2008) Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 3-4: 194-196.
45. Fitzgerald KA, Golenbock DT (2007) Immunology. The shape of things to come. Science 5831: 1574-1576.
46. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 5831: 1628-1632.
47. Nerenberg ST and Prasad R (1975) Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 5: 887-898.
48. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, et al. (1990) A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 3: 263-270.
49. Banks WA (2010) Immunotherapy and neuroimmunology in Alzheimer's disease: a perspective from the blood-brain barrier. Immunotherapy 1: 1-3.
50. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 8: 916-919.
51. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, et al. (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 5: 360-371.
52. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5: 347-360.
53. Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 3: 285-299.
54. Zhang Y and Lee DH (2011) Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 2: 163-173.
55. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, et al. (2012) Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach. Curr Alzheimer Res 4: 397-405.
56. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. Journal of Neuroscience 34: 9115-9129.
57. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, et al. (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2: 472-485.
58. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. Journal of Neuroscience 49: 16559-16566.
59. Boutajangout A, Ingadottir J, Davies P, and Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 4: 658-667.
60. Bi M, Ittner A, Ke YD, Gotz J, and Ittner LM (2011) Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS One 12: e26860.
61. Chai X, Wu S, Murray TK, Kinley R, Cella CV, et al. (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 39: 34457-34467.
62. d'Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS One 4: e62402.
63. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 6: 857-868.
64. Urushitani M, Ezzi SA, and Julien JP (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 7: 2495-2500.
65. Kuret J, Chirita CN, Congdon EE, Kannanayakal T, Li G, et al. (2005) Pathways of tau fibrillization. Biochim Biophys Acta 2-3: 167-178.
66. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, et al. (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. Journal of Neuroscience 14: 3650-3662.
67. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, et al. (2011) Characterization of prefibrillar tau oligomers in vitro and in Alzheimers disease. J Biol Chem.
68. Kremer A, Louis JV, Jaworski T, and van LF (2011) GSK3 and Alzheimer's Disease: Facts and Fiction... Front Mol Neurosci 17.
69. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, et al. (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. Journal of Neuroscience 37: 13110-13117.
70. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 7: 909-913.
71. Frost B, Jacks RL, and Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 19: 12845-12852.
72. Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 4: 301-307.